H.C. Wainwright raised the firm’s price target on Adagene (ADAG) to $8 from $5 and keeps a Buy rating on the shares. The company presented positive data from its ongoing Phase 1/2 study with ADG126, the analyst tells investors in a research note. The firm says safety and repeat dosing could be the differentiating factors.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ADAG: